Interleukin-6 (IL-6) plays a critical role in creating an immunosuppressive microenvironment that contributes to treatment resistance in glioblastoma, one of the most aggressive primary brain tumors. This research identifies IL-6 as a key mediator of immune evasion mechanisms, highlighting its potential as a therapeutic target. Understanding the molecular pathways through which IL-6 promotes immunosuppression and therapy resistance offers promising avenues for developing combination treatment strategies that could enhance patient outcomes in glioblastoma management.

Organoids and Organ-on-a-Chip technology have been considered a paradigm shift in cell culture for over a decade. However, fundamental usability and logistics aspects have hampered widespread adoption, as both require deep biological expertise and cumbersome logistics of cell materials. MIMETAS has invested in productization of organoids in its perfused high throughput OrganoPlate platform. Its OrganoReady® product line comprises of 64 adult stem cell derived colon organoids grown as perfused tubules that are delivered ready-to-use to the bench of the scientist. Turnkey assays allow monitoring of barrier function under toxic and inflammatory challenges. New products for the kidney are available in early access, and next generation models comprising fully vascularized, stroma and immune competent liver, lung and tumor tissues are available in a services setting.

Researchers have developed a novel oncolytic herpes simplex virus type 2 (OH2) as a potential treatment for glioblastoma multiforme, an aggressive brain tumor with poor prognosis. The study demonstrates that OH2 induces direct tumor cell death while simultaneously reprogramming the immunosuppressive tumor microenvironment. Specifically, the virus polarizes tumor-associated macrophages toward an anti-tumor phenotype, thereby enhancing the immune response against cancer cells. Through comprehensive in vitro and in vivo experiments combined with clinical observations from recurrent glioblastoma patients, the research reveals OH2's dual mechanism of action—direct cytotoxicity and immune modulation—suggesting a promising therapeutic approach to overcome the profound immunosuppression characteristic of glioblastoma and improve treatment outcomes.

Gliomas, particularly glioblastoma, secrete extracellular vesicles that serve as critical mediators of immune suppression within the tumor microenvironment. These vesicles carry bioactive molecules including immune checkpoint proteins, non-coding RNAs, and metabolic regulators, enabling communication across the blood-brain barrier and linking local to systemic immune responses. This review examines how glioma-derived extracellular vesicles drive immunotherapeutic resistance through multiple mechanisms. Specifically, vesicle-associated PD-L1 engages T-cell PD-1 receptors more effectively than membrane-bound variants, promoting broader immunosuppression. Additionally, these vesicles expand myeloid-derived suppressor cells, polarize macrophages and microglia toward immunosuppressive states, and impair dendritic cell function, collectively driving T-cell dysfunction. Non-coding RNAs enriched in vesicles further regulate critical signaling pathways. Understanding these mechanisms offers potential therapeutic targets for metabolic and immune interventions to overcome treatment resistance.

This comprehensive study presents a pan-cancer atlas of tumor-associated macrophages (TAMs) integrating single-cell and spatial transcriptomic data from 291 human samples across 16 cancer types, identifying 28 TAM subtypes. The research elucidates TAM spatial distribution patterns within the tumor microenvironment and their functional heterogeneity, revealing critical crosstalk mechanisms. TAMs localized in peritumoral and core tumor regions promote angiogenesis and metabolic reprogramming, while also suppressing CD8+ T cell function to establish immunosuppressive conditions. The study highlights how cancer-associated fibroblasts regulate TAM polarization and recruitment through the SPP1 and integrin/CD44 signaling axes, ultimately facilitating tumor invasion, metastasis, and immune evasion. These findings provide fundamental insights into TAM biology with significant implications for understanding tumor progression and developing immunotherapeutic strategies.

Researchers have developed an innovative perfused microfluidic platform to address the critical challenge of drug delivery across the blood-brain barrier for treating brain tumors. This in vitro system integrates a human blood-brain barrier model with tumor spheroids in a physiologically relevant environment, featuring 32 parallel testing units in a convenient well-plate format. The platform employs gravity-driven flow to create realistic shear stress conditions without requiring external pumps, enabling efficient, high-throughput screening. Testing four FDA-approved chemotherapeutic agents on patient-derived glioma models revealed that the blood-brain barrier significantly restricts drug penetration to tumors. This innovative tool promises to enhance understanding of drug permeation dynamics and facilitate more effective therapeutic development for currently challenging neurological malignancies.

Researchers at Washington University School of Medicine have demonstrated that a personalized DNA vaccine shows promise in treating glioblastoma, an aggressive and typically incurable brain cancer. In this early-stage clinical trial, the vaccine proved safe and generated robust immune responses, potentially extending recurrence-free survival in certain patients following surgery. Notably, patients with the most aggressive glioblastoma variant experienced no serious side effects and showed prolonged overall survival compared to standard treatment outcomes. One patient remains recurrence-free after nearly five years. The vaccine works by engineering DNA molecules tailored to each patient's unique tumor proteins, stimulating targeted immune responses. These encouraging phase one results, published in Nature Cancer, suggest significant potential for personalized cancer immunotherapy and warrant further investigation into combination approaches.

Glioblastoma is a highly aggressive brain tumor whose treatment has improved little over the past decade. We report on the synergistic effect of the FDA-approved anti-GBM drug (temozolomide) and inhibitors (acriflavine, PT2385) of hypoxia-inducible factors (HIFs) embedded into coaxial fiber membranes (NanoMesh). In vitro cytotoxicity has been evaluated for various glioma cell lines, and synergistic drug combinations have been identified. Preliminary animal studies with the three-drug-loaded NanoMesh indicate a significant improvement of median survival of >50 days and long-term (>120 days) survival rate of 40%, indicating the potential of this material platform as a translatable local GBM therapy.

Researchers developed a personalized DNA cancer vaccine that has shown promising results in an early-stage clinical trial for glioblastoma. The study demonstrates that the vaccine, GNOS-PV01, is safe and elicits a broad immune response that appears to increase survival rates in patients with particularly aggressive, “unmethylated” forms of this incurable brain cancer.

A personalized glioblastoma vaccine appears safe and may help extend survival in early trial results. The treatment trains the immune system to attack multiple tumor targets, making it harder for the cancer to evade. Some patients lived longer than expected, including one who remains cancer-free nearly five years later.

Glioblastoma (GBM) is known for its aggressive biology. It can also demonstrate significant resistance to standard therapies. Therefore, before discussing "why" patients should consider immunotherapy (IT) for GBM, we would like to explain the unique challenges that glioblastoma cells can pose; the reasons why current GBM treatments often fail; and how utilizing the body's immune defenses can potentially increase survival of patients with brain tumors.

Lipid nanoparticles (LNPs) have emerged as a promising delivery platform for complex therapeutics targeting the central nervous system, addressing significant challenges posed by the blood–brain barrier. While peripheral administration of biotherapeutics such as antibodies, immunotherapeutics, and gene therapies has traditionally been limited by anatomical barriers, recent advances in LNP technology offer compelling alternatives to viral vectors. By leveraging receptor-mediated transcytosis mechanisms and functionalizing LNPs with blood–brain barrier-penetrant moieties, researchers are successfully enabling CNS delivery of various therapeutic modalities, including messenger RNA, small interfering RNA, and antisense oligonucleotides. These innovations, validated through preclinical models and emerging clinical studies, represent a transformative approach to treating neurological indications and expanding the therapeutic potential of advanced biotherapeutics.

Emotiv provides advanced brain data measurement hardware and software solutions designed to enhance scientific understanding of glioblastoma, a highly aggressive form of brain cancer. The platform leverages cutting-edge neurotechnology to capture and analyze brain activity patterns, enabling researchers to gain deeper insights into disease mechanisms and treatment responses. By combining non-invasive brain imaging with sophisticated data analytics, Emotiv's solutions support the development of more targeted therapeutic interventions and personalized treatment strategies. These innovations represent a significant advancement in oncology research, offering hope for improved patient outcomes through better diagnostic and monitoring capabilities in glioblastoma management.

China has emerged as a leading hub for advanced glioblastoma treatment through CAR-T cell therapy, with over 66 clinical trials launched across major medical institutions between 2022 and 2025. Chinese researchers are pioneering multi-antigen targeting strategies using dual or tri-specific CAR-T cells to overcome tumor resistance, while innovative manufacturing platforms have dramatically reduced production times from weeks to 24-36 hours. Estimated costs for experimental CAR-T therapy in investigator-initiated trials range from $40,000 to $80,000. This represents a significant advancement for glioblastoma patients, as conventional Western treatment protocols yield median overall survival of only 12-15 months initially and 6-8 months upon recurrence. International patients increasingly explore these cutting-edge therapies at JCI-accredited neuro-oncology centers targeting critical antigens such as EGFRvIII and HER2, marking a paradigm shift in neurological oncology treatment options.

This large real-world cohort study examines the clinical, molecular, and immunologic factors that influence survival outcomes in patients with WHO-defined IDH-wildtype glioblastoma treated with radiotherapy. Conducted by researchers at the University of Pennsylvania's Department of Radiation Oncology, the investigation identifies key prognostic determinants across multiple biological dimensions. By integrating clinical characteristics with molecular profiling and immunologic markers, the study provides comprehensive insights into treatment response and patient prognosis. These findings enhance our understanding of glioblastoma heterogeneity and may inform personalized treatment strategies to optimize radiotherapy outcomes in this aggressive brain tumor population.

Le cancer du cerveau appelé glioblastome, un type de tumeur cérébrale vraiment difficile, pose de sérieux défis aux médecins et aux patients. Il est connu pour être agressif et difficile à traiter, revenant souvent même après un traitement. Cet article examine pourquoi le glioblastome est si difficile à traiter, ce qui le fait fonctionner au niveau cellulaire, et les nouvelles idées que les chercheurs explorent pour le combattre.

One UNC Healthclinical trialbegun in 2022 intends to evaluate the safety and patients’ toleration of chimeric antigen receptor T-cell therapy. The trial is treating patients whose cancer has not successfully responded to one or more treatments. The CAR-T process involves extracting specific immune cells from patients, engineering the cells in a lab to identify tumor cells displaying a specific molecular target, then re-infusing the cells to fight the patient’s brain tumor. Now programmed to have “chimeric antigen receptors” or CARs, the T-cells latch onto tumor cells and destroy them.  

Blood–brain barrier tight junctions, efflux transporters, and poor tissue diffusion necessitate systemic agents with improved CNS exposure, without relying on infeasible surgical completeness or inconsistent local delivery platforms. Intratumoral heterogeneity and antigen loss drive resistance to single-antigen biologics, supporting multispecific constructs that engage multiple targets and/or recruit effector cells to counter clonal evolution. Immunosuppressive GBM microenvironment limits checkpoint and CAR T efficacy via inhibitory cytokines, Treg activity, and PD-L1 upregulation, motivating therapeutics that locally modulate immune function.

Emerging evidence reveals the pivotal involvement of mitochondrial metabolic dysregulation in glioblastoma (GBM) pathogenesis, considering mitochondrial metabolism as a potential therapeutic target. Nebivolol, a third-generation β-adrenergic receptor antagonist clinically employed in cardiovascular diseases, has recently exhibited notable anti-neoplastic properties. Nevertheless, its therapeutic efficacy and mechanistic underpinnings in GBM remain largely unexplored. In this investigation, we comprehensively assessed the impact of nebivolol on GBM cellular proliferation and elucidated its molecular mechanisms. Our findings revealed that nebivolol markedly suppressed the proliferation and clonogenic abilities of multiple GBM cell lines, concomitant with cell cycle arrest and apoptotic induction.

The clinical, neuroradiological and surgical definition of hypothalamic involvement is a fundamental factor related to poor postoperative outcome, progressive obesity and neuropsychological impairment in children after surgical removal of craniopharyngiomaThe previously assumed 'gold-standard' objective of a primary radical removal of the lesion in all cases needs to be replaced with the new paradigm of a limited resection plus focused radiotherapy in patients with craniopharyngioma and hypothalamic lesions